Janssen Research & Development, a unit of Johnson & Johnson, has submitted a supplemental new drug application to the Food and Drug Administration (FDA) updating the prescribing information for its blood thinner Xarelto. Janssen seeks to add a 10 mg dose to reduce patients’ risk of recurrent venous thromboembolism. Xarelto was approved by the FDA in 2011. Xarelto is currently prescribed in 20 or 15 mg once-daily doses for stroke prevention in atrial fibrillation, and 10 mg once-daily doses for blood clot prevention for 12 days in patients who recently underwent knee replacement surgery and 35 days in patients who ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.